5 Pharmaceutical Price Target Raises From Jefferies

Jefferies' Jeffrey Holford raised five pharmaceuticals following key news on each company's products:

• Abbott ABT increased the price target to $45.00 after Abbot reported positive results from Type-1 Diabetes study. The study showed that Abbott system's significantly reduced Hypoglycemia.
• Bristol-Myers Squibb Company BMY raised the price objective to $78.00 after the company announced new data demonstrating continued research expansion and Immuno-Oncology Advancements across multiple blood cancers. Additionally, Bristo-Myers Squibb announced new data on Opdivo which indicated benefit in heavily pre-treated classical Hodgkin Lymphoma Patients in Phase 2.
• Johnson and Johnson JNJ price target raised to $109.00 after it announced EPREX demonstrated effectiveness as treatment for Anaemia in patients with low or intermediate-1 risk of Myelodysplastic syndromes at EHA Saturday.
• Pfizer PFE's price target rose to $42.00 after the company announced two pivotal phase 3 studies for Ertuglifozin Met Primary Endpoints, showing significant A1C reductions in patients with Type 2 Diabetes at the American Diabetes Association's 76th scientific sessions Sunday.
• Zoetis ZTS increased the price objective to $58.00 after Zoetis shares rose considerably over the last three months.